ALGS — Aligos Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $61.45m
- -$61.33m
- $3.95m
- 30
- 32
- 90
- 49
Annual income statement for Aligos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 4.36 | 13.9 | 15.5 | 3.94 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 97.8 | 133 | 111 | 104 | 93.1 |
| Operating Profit | -97.8 | -128 | -97.6 | -88.1 | -89.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -108 | -128 | -95.9 | -86.9 | -131 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -109 | -128 | -96 | -87.7 | -131 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -109 | -128 | -96 | -87.7 | -131 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -109 | -128 | -96 | -87.7 | -131 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -74.1 | -80.5 | -56.2 | -32.6 | -20.5 |